Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Accumulated Expenses (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Other Accumulated Expenses for 8 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 39.73% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2025, down 39.73%, and an annual FY2025 reading of $1.4 million, down 39.73% over the prior year.
  • Other Accumulated Expenses was $1.4 million for Q4 2025 at Zevra Therapeutics, down from $9.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $9.0 million in Q3 2025 and bottomed at $302000.0 in Q1 2023.
  • Average Other Accumulated Expenses over 5 years is $2.2 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses surged 1001.67% in 2021, then crashed 75.19% in 2023.
  • Year by year, Other Accumulated Expenses stood at $836000.0 in 2021, then fell by 24.76% to $629000.0 in 2022, then skyrocketed by 388.08% to $3.1 million in 2023, then fell by 26.38% to $2.3 million in 2024, then crashed by 39.73% to $1.4 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ZVRA at $1.4 million in Q4 2025, $9.0 million in Q3 2025, and $6.9 million in Q2 2025.